Corticosteroid Therapy in Canine Atopic Dermatitis: Dosing and Monitoring

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Prednisolone or prednisone are the preferred first-line systemic corticosteroids for canine atopic dermatitis, with short-acting oral formulations favored for their titratability and reduced HPA axis suppression compared to depot injectables.
• Induction therapy involves daily oral dosing for 5-14 days to rapidly control pruritus and inflammation, followed by a gradual taper to the lowest effective alternate-day or every-third-day maintenance dose to minimize adverse effects.
• Monitoring for adverse effects is critical and includes baseline and periodic assessment of body weight, blood pressure, urinalysis (including urine culture if indicated), and serum biochemistry to detect complications like iatrogenic hyperadrenocorticism, urinary tract infections, and calcinosis cutis.
• Topical corticosteroid potency must be matched to lesion location and severity, with low-potency agents used on thin-skinned areas like the face and groin to prevent atrophy and systemic absorption.
• Reassessment of the diagnosis is mandatory if daily corticosteroid dosing is required beyond 3-4 weeks, as this may indicate secondary infection, contact allergy, or an incorrect primary diagnosis.
• Corticosteroid therapy should be considered in conjunction with strategies that support epidermal barrier repair, as barrier dysfunction is a hallmark of canine atopic dermatitis and is not directly addressed by corticosteroids alone.

This article provides practical guidance for the practicing veterinarian on the use of corticosteroids in canine atopic dermatitis (AD). It covers the pharmacological rationale for corticosteroid selection, dosing strategies for induction and maintenance, and structured monitoring protocols for adverse effects. The content assumes familiarity with the diagnosis of canine AD and focuses on therapeutic decision-making instead of diagnostic workup. Alternative therapies, including calcineurin inhibitors and allergen-specific immunotherapy, are excluded except where they inform corticosteroid safety considerations.

The clinical questions addressed are direct: which corticosteroid to choose, at what dose, for how long, and what to check during therapy. The evidence base for corticosteroid use in canine AD draws heavily on extrapolation from human dermatology and from clinical pharmacology studies in dogs. Where the veterinary literature is limited, this is stated explicitly.

At a Glance

Pathophysiology of Canine Atopic Dermatitis and the Role of Corticosteroids

Canine AD is a genetically predisposed, chronic inflammatory and pruritic skin disease driven by cutaneous dysregulation of the immune response. The epidermal barrier is disturbed even in non-lesional skin, allowing environmental allergens to penetrate and trigger inflammation through immunologic pathways. This barrier dysfunction is a hallmark of the disease and influences both disease chronicity and therapeutic response. Topical therapy with potent corticosteroids does not repair this barrier defect, whereas certain non-corticosteroid agents support barrier repair. This distinction matters clinically because corticosteroid monotherapy may control inflammation without addressing the underlying barrier abnormality.

Corticosteroids exert their anti-inflammatory effect through intracellular glucocorticoid receptor binding, leading to transrepression of pro-inflammatory cytokine genes and transactivation of anti-inflammatory mediators. In canine AD, the dominant clinical benefit is rapid suppression of pruritus and erythema through reduction of cutaneous inflammation. The onset of action for oral prednisolone is typically within 24 to 48 hours, which makes corticosteroids the most rapidly effective symptomatic therapy available for acute flares.

Corticosteroid Selection and Formulation Considerations

Systemic Corticosteroids

Oral prednisolone and prednisone remain the most commonly used systemic corticosteroids for canine AD. Prednisolone is the active metabolite and does not require hepatic conversion, whereas prednisone requires hepatic 11-beta-hydroxysteroid dehydrogenase activity to become active. Most dogs convert prednisone adequately, but prednisolone is preferred in patients with hepatic disease or when a more predictable response is desired.

The choice between short-acting and long-acting formulations is clinically significant. Short-acting oral corticosteroids such as prednisolone and methylprednisolone allow alternate-day dosing and produce less hypothalamic-pituitary-adrenal (HPA) axis suppression than long-acting injectable formulations. Depot injectable corticosteroids such as methylprednisolone acetate are discouraged for canine AD because their duration of action is unpredictable, they cannot be titrated to response, and they produce prolonged HPA suppression. Current formulary references should be consulted for specific product availability and dosing guidance.

Topical Corticosteroids

Topical corticosteroids are useful for localized lesions, particularly on the paws, pinnae, and ventral abdomen. Potency selection follows the same principles as in human dermatology: low-potency agents for thin-skinned areas such as the face, axillae, and groin, and higher-potency agents for thick-skinned or lichenified areas. Hydrocortisone and other low-potency products are appropriate for facial and intertriginous lesions. Potent topical corticosteroids should be avoided in these regions due to the risk of skin atrophy and systemic absorption.

Topical corticosteroid use in canine AD is limited by the extent of lesional skin. Patients with generalized disease are better managed with systemic therapy. The owner should be instructed to apply topical products only to lesional skin and to prevent licking of treated areas.

Dosing Strategies

Induction Phase

The goal of induction therapy is rapid control of pruritus and visible inflammation. Oral prednisolone is initiated at a daily dose sufficient to suppress clinical signs. The dose is continued daily until pruritus scores and lesion severity have substantially improved, which typically requires 5 to 14 days. If there is no meaningful response within 7 days of daily therapy, the diagnosis should be reconsidered. Poor response to an adequate corticosteroid trial raises the possibility of a secondary infection, contact allergy, or an incorrect primary diagnosis.

Maintenance Phase

Once control is achieved, the dose is tapered. The standard approach is to reduce the frequency from daily to alternate-day administration, then to every third day, before discontinuing. The dose on treatment days may also be reduced. The objective is to identify the lowest dose and frequency that maintains acceptable control. Some dogs require long-term alternate-day therapy, while others can be weaned off corticosteroids entirely during periods of low allergen exposure.

Alternate-day therapy is preferred over daily therapy because it permits HPA axis recovery on the off day. The taper should be gradual. Abrupt withdrawal after more than 3 weeks of daily therapy risks iatrogenic hypoadrenocorticism.

Monitoring for Adverse Effects

Corticosteroid adverse effects in dogs are dose-dependent and duration-dependent. The most common early effects are polyuria, polydipsia, polyphagia, and panting. These are expected at anti-inflammatory doses and typically resolve as the dose is tapered. Their persistence at maintenance doses warrants dose reduction.

Urinary tract infection is a well-recognized complication of corticosteroid therapy in dogs. Glucocorticoids suppress the local immune response, and many affected dogs are asymptomatic. A urinalysis should be performed at baseline and at each recheck examination during maintenance therapy. Urine culture is indicated if pyuria or bacteriuria is detected on sediment examination.

Cutaneous adverse effects include calcinosis cutis, skin atrophy, and delayed wound healing. Calcinosis cutis presents as firm, gritty dermal papules or plaques, often on the dorsum or pressure points, and is more common with potent or prolonged therapy. Iatrogenic hyperadrenocorticism is a risk with chronic daily dosing and is characterized by alopecia, abdominal distension, and hepatomegaly.

Blood pressure should be measured at baseline and periodically during therapy. Glucocorticoids can elevate blood pressure, and sustained hypertension contributes to retinopathy and nephropathy. Serum biochemistry should be monitored for elevations in alkaline phosphatase, which reflects hepatic enzyme induction and is expected with corticosteroid therapy. Marked or progressive elevations warrant investigation.

Evidence Limitations and Clinical Judgment

The veterinary literature on corticosteroid dosing for canine AD is largely empirical. Controlled trials comparing different corticosteroid protocols in dogs are limited, and much of the dosing framework is extrapolated from human dermatology and from clinical experience. The human literature confirms that topical corticosteroids are first-line therapy for AD but are associated with significant adverse effects when used chronically. Similar caution applies to systemic corticosteroid use in dogs.

The approved evidence set for this article includes sources on the epidermal barrier in atopic dermatitis, which supports the recommendation that corticosteroid therapy should be combined with barrier repair strategies where feasible. It also includes regulatory and professional resources that inform judicious prescribing and adverse event reporting. Practitioners should consult current veterinary pharmacology references for specific product information and should report suspected adverse drug reactions through the appropriate regulatory channels.

Pretreatment Assessment and Case Selection

The decision to initiate corticosteroid therapy begins with a complete diagnostic workup. Canine atopic dermatitis is a diagnosis of exclusion, and the clinician must rule out ectoparasites, dermatophytosis, and bacterial or Malassezia overgrowth before committing to long-term anti-inflammatory therapy. Skin cytology, trichography, and appropriate parasite testing should be performed at every relapse, also at initial presentation, because secondary infections alter both the clinical picture and the response to corticosteroids.

Patient selection matters as much as drug selection. Corticosteroids are appropriate for induction of remission in moderate to severe pruritus where the diagnosis is confirmed and trigger avoidance has failed. They are less suitable as sole long-term therapy in dogs that require continuous suppression, where steroid-sparing agents or multimodal approaches should be considered. Breed predisposition to steroid-responsive dermatoses, such as the allergic-like dermatitis seen in West Highland White Terriers, does not alter the monitoring obligations.

Comorbidities change the risk calculus. Dogs with diabetes mellitus, hyperadrenocorticism, pancreatitis, renal insufficiency, or a history of gastrointestinal ulceration tolerate systemic corticosteroids poorly. Hepatic disease slows corticosteroid metabolism and prolongs effect. Geriatric patients and those with marginal cardiac reserve may decompensate with the sodium and water retention associated with mineralocorticoid activity. For these patients, topical therapy or alternative anti-inflammatory classes should be prioritized where feasible. The epidermal barrier is already disturbed in atopic dermatitis, and topical corticosteroid potency must be matched to lesional skin thickness and location, as barrier dysfunction influences percutaneous absorption.

Induction and Taper Protocols

Systemic corticosteroid therapy follows a structured induction, taper, and maintenance sequence. The induction phase uses a higher dose to break the itch-scratch cycle, typically for 3 to 7 days. Once pruritus is controlled, defined as a visible reduction in scratching and self-trauma, the taper begins. The taper should be gradual, with dose reductions every 5 to 7 days, instead of abrupt discontinuation, to avoid rebound flares and to identify the minimum effective dose.

A representative taper schedule for oral prednisolone or prednisone is shown below. Current formulary references must be consulted for starting doses, as published ranges vary by preparation and clinical context.

Alternate-day dosing is preferred for maintenance. Giving the total maintenance dose every 48 hours reduces hypothalamic-pituitary-adrenal axis suppression while preserving anti-inflammatory effect. The conversion is made by doubling the daily maintenance dose and administering it every other morning. If pruritus returns during the taper, the clinician should return to the last dose that controlled signs, confirm the absence of secondary infection, and reconsider the diagnosis or the suitability of corticosteroid monotherapy.

Topical corticosteroids follow a different protocol. Potent products are used for 5 to 7 days on lichenified or thickened lesions, then stepped down to a lower potency product or reduced frequency. Facial and intertriginous areas require lower potency formulations because of thinner skin and higher absorption. Topical therapy is appropriate for localized disease, but generalized canine atopic dermatitis usually requires systemic therapy or a combination approach.

Monitoring Parameters and Frequency

Monitoring serves two purposes: detecting dose-limiting adverse effects and confirming that the therapy remains appropriate. The monitoring plan is stratified by treatment duration and systemic exposure.

For short courses of less than 2 weeks, monitoring is largely clinical. The owner should report polydipsia, polyuria, polyphagia, panting, lethargy, or gastrointestinal signs. These effects are common and often dose-dependent, and they typically resolve as the dose is tapered. Routine laboratory testing is not required for brief courses in otherwise healthy dogs.

For therapy extending beyond 4 weeks, or for any dog receiving systemic corticosteroids with comorbidities, laboratory monitoring is indicated. A baseline complete blood count, serum biochemistry profile, and urinalysis should be obtained before starting long-term therapy. Repeat testing every 3 to 6 months is reasonable, with additional testing prompted by clinical signs.

Calcinosis cutis is a late and serious complication of prolonged corticosteroid exposure. It presents as firm, gritty dermal papules or plaques, often over the dorsum or pressure points, and may ulcerate. Its presence mandates immediate and gradual withdrawal of corticosteroids, as rapid discontinuation can precipitate hypoadrenocorticism.

Managing Adverse Effects and Treatment Failure

Adverse effects are managed by dose reduction, frequency modification, or drug withdrawal, not by adding therapies that mask the problem. Polyuria and polydipsia are expected at anti-inflammatory doses and are not themselves indications to stop therapy. The decision point is whether the effect compromises quality of life, whether it persists at the minimum effective dose, or whether it signals a developing complication such as diabetes mellitus.

Treatment failure has a defined differential. The most common cause is inadequate dose, either because the induction dose was too low or the taper was too rapid. The second is secondary infection, which requires systemic antimicrobial or antifungal therapy instead of higher corticosteroid doses. The third is misdiagnosis, particularly when the dog has a food-responsive dermatosis, flea allergy, or a contact allergy that was not fully excluded. The fourth is poor owner compliance with topical therapy or difficulty applying products to affected areas.

When a dog fails to respond to appropriate corticosteroid doses, the clinician should stop, reassess, and consider referral for intradermal testing or allergen-specific immunotherapy. Continuing corticosteroids in the face of non-response exposes the patient to adverse effects without therapeutic benefit. The evidence base for corticosteroid dosing in canine atopic dermatitis is drawn largely from extrapolation of human data and clinical experience, and individual responses vary considerably. This uncertainty supports a conservative approach: use the lowest effective dose, taper deliberately, and monitor systematically.

Recognized Complications and Early Detection

The principal complications of corticosteroid therapy in canine atopic dermatitis are iatrogenic hyperadrenocorticism, cutaneous atrophy, calcinosis cutis, urinary tract infection, and secondary bacterial or Malassezia pyoderma. Each has a characteriztic time course and a practical screening method.

Iatrogenic hyperadrenocorticism develops insidiously with prolonged daily dosing. Early signs include polyuria, polydipsia, polyphagia, panting, and a pendulous abdomen. Owners frequently attribute these to aging or obesity. Detect early by asking specifically about water consumption at every recheck and by measuring urine specific gravity when polydipsia is reported. A persistently dilute urine in a dog receiving glucocorticoids warrants dose reduction even before overt signs appear.

Cutaneous atrophy presents as thin, fragile skin, prominent vessels, and easy bruising. It is most visible on the ventral abdomen and pinnae. Calcinosis cutis appears as firm, white, gritty papules or plaques, often on the dorsum or pressure points. Both indicate excessive cumulative exposure and mandate a switch to alternate-day therapy or a steroid-sparing agent. Topical potent corticosteroids applied to the face or flexural surfaces can produce local atrophy and comedones, particularly in breeds predisposed to demodicosis.

Urinary tract infection is a frequently missed complication. Glucocorticoids suppress clinical signs of cystitis, so pyuria and bacteriuria may be present without dysuria. Perform a urinalysis with culture at each monitoring visit if the dog has received systemic corticosteroids for more than two months. Recurrent or ascending infection can develop without overt lower urinary tract signs.

Secondary pyoderma and Malassezia dermatitis complicate the disease itself, but corticosteroid dose escalation in response to pruritus without treating the infection is a common failure mode. The skin barrier is already disturbed in atopic dermatitis, and inflammation permits microbial overgrowth. Pruritus that fails to respond to an adequate corticosteroid dose should prompt cytological evaluation of lesional skin before any dose increase. The epidermal barrier does not repair under potent topical corticosteroid therapy, whereas calcineurin inhibitors and lipid-containing emulsions support barrier repair, a distinction relevant when choosing long-term maintenance.

Common Errors and Corrective Actions

The most frequent error is using a short-acting corticosteroid once daily instead of a longer-acting agent on an alternate-day schedule. This produces greater hypothalamic-pituitary-adrenal axis suppression with less consistent pruritus control. Correct by selecting a formulation with a duration of action that permits every-other-day administration and by tapering the dose, also the frequency, during the maintenance phase.

A second error is treating pruritus as a single endpoint without reassessing lesion distribution. Eyelid dermatitis, for example, is often multifactorial, allergic contact dermatitis was the most common cause in a large case series, and atopic dogs may have concurrent contact allergy. Corticosteroids will suppress the atopic component but not the contact component, leading to apparent treatment failure. Patch testing should be considered when facial or eyelid pruritus persists despite adequate systemic therapy.

A third error is escalating the corticosteroid dose when pruritus worsens without first excluding infection, ectoparasites, or dietary indiscretion. The corrective action is a structured re-evaluation: cytology, skin scraping, and a review of owner compliance with parasiticides and diet.

Finally, abrupt discontinuation after prolonged therapy can precipitate hypoadrenocorticism. The taper must be gradual, and the clinician should distinguish between rebound pruritus, which responds to a temporary small dose increase, and glucocorticoid withdrawal syndrome, which does not.

Troubleshooting Table

Evidence Limitations and Divergent Expert Opinion

The evidence base for corticosteroid dosing in canine atopic dermatitis relies heavily on extrapolation from human dermatology and on clinical experience instead of controlled canine trials. Human data show that topical corticosteroids are first-line therapy but carry significant adverse effects with chronic use, and that calcineurin inhibitors offer an alternative with a different safety profile. Whether these findings transfer directly to dogs is uncertain, particularly regarding the relative potency of topical products across species.

Expert opinion differs on three points. First, the acceptable duration of induction therapy before a steroid-sparing agent is introduced varies widely, from two weeks to several months. Second, some dermatologists favour topical therapy as the primary modality even in moderate disease, while others argue that systemic therapy achieves faster control and better owner compliance. Third, the role of adjunctive barrier repair is debated. The skin barrier is disturbed even in non-lesional atopic skin, and topical corticosteroids do not restore it, but whether routine barrier emollients meaningfully reduce corticosteroid requirements has not been established in dogs.

Referral and Reporting

Referral to a veterinary dermatologist is warranted when pruritus does not respond to an adequate corticosteroid trial, when the diagnosis is uncertain, when calcinosis cutis or severe cutaneous atrophy develops, or when the maintenance dose remains above a level associated with unacceptable adverse effects. Dermatologists can perform intradermal testing, allergen-specific immunotherapy, and more sophisticated cytological and histopathological evaluation.

Laboratory involvement is indicated for baseline assessment and for monitoring. A biochemistry panel, urinalysis, and urine culture should be performed before long-term therapy and repeated at intervals dictated by the dose and duration. Adrenal function testing is reserved for suspected iatrogenic hyperadrenocorticism or withdrawal syndrome.

Regulatory reporting obligations vary by jurisdiction. In the United States, adverse drug events associated with approved animal drugs should be reported to the FDA Center for Veterinary Medicine, which maintains the adverse event reporting system for animal drugs. Clinicians should be aware that extralabel use of corticosteroids in dogs is common and generally permitted under the Animal Medicinal Drug Use Clarification Act, but the prescriber assumes responsibility for establishing a valid veterinarian-client-patient relationship and for documenting the basis for extralabel use. International practitioners should consult their own regulatory authority, as requirements differ. Professional guidance on judicious drug use and stewardship is available from organizations such as the AVMA, which publishes practice resources for veterinarians.

Frequently Asked Questions

How Should I Adjust Corticosteroid Dosing When the Client Cannot Afford Frequent Recheck Examinations?

When financial constraints limit rechecks, extend the interval between dose reductions instead of shortening it, and ask the owner to monitor weight, appetite, water intake, and urination at home. Prescribe the smallest tube or bottle size that will complete the taper, and request a single recheck at the midpoint of the maintenance phase instead of multiple visits. If laboratory monitoring is unaffordable, prioritize a baseline biochemistry panel before starting therapy and one panel after four to six weeks of treatment. Document the reduced monitoring plan in the medical record and explain to the owner which clinical signs, such as polyuria, polydipsia, or panting, should prompt a return visit even without an appointment.

What Should I Do When Topical Corticosteroid Application Is Impractical for a Large-Breed Dog with Widespread Lesions?

For a large dog with generalized disease, topical therapy becomes logistically difficult and systemically absorbed drug may approach levels seen with oral treatment. In this situation, systemic corticosteroids are usually more practical, and the topical route should be reserved for localized areas such as the paws, ears, or face. If the owner insists on topical therapy, select a spray or lotion formulation that covers larger surface areas more efficiently than an ointment, and instruct the owner to apply it only to lesional skin. Remember that potent topical corticosteroids do not repair the epidermal barrier in atopic dermatitis, so concurrent barrier support with lipid-containing emulsions remains important regardless of route.

How Do I Manage a Dog That Relapses Immediately After Each Corticosteroid Taper?

Rapid relapse after tapering suggests the induction dose was insufficient, the taper was too fast, or the diagnosis is incomplete. Re-evaluate the dog for secondary infections, flea allergy dermatitis, or food-responsive disease before assuming the corticosteroid dose was wrong. If infection and other pruritic diseases are excluded, restart induction at the original dose and taper more slowly, reducing by smaller increments at each step. Consider whether the maintenance phase should use alternate-day dosing instead of daily dosing, as this may preserve efficacy while reducing cumulative exposure. If the dog requires prolonged daily dosing to control signs, revisit the diagnosis and discuss referral for allergen-specific immunotherapy, since corticosteroid-sparing strategies reduce long-term risk.

What Records Should I Maintain for a Dog on Long-Term Corticosteroid Therapy?

Maintain a treatment log that includes the drug name, formulation, starting dose, each dose reduction with dates, and the clinical response at each step. Record body weight at every visit, and note any change in body condition score, muscle mass, or abdominal distension. Document baseline and follow-up laboratory results, including biochemistry panels and urinalysis, with dates clearly linked to the current dose. Note any adverse effects observed or reported, the action taken, and the outcome. This record supports defensible clinical decisions if the case is later reviewed, and it helps the next clinician understand the dog's response trajectory. The FDA Center for Veterinary Medicine provides resources on adverse event reporting that may apply if an unexpected reaction occurs.

How Should I Explain Corticosteroid Risks to an Owner Who Has Read Negative Information Online?

Acknowledge the owner's concern directly, then frame the discussion around dose, duration, and monitoring instead of the drug class alone. Explain that short courses at anti-inflammatory doses carry low risk, while the risks of polyuria, polydipsia, weight gain, and calcinosis cutis increase with prolonged daily use. Describe the monitoring plan in concrete terms, such as blood tests at specific time points and weight checks at each visit, so the owner sees that risks are actively managed. Emphasize that the goal is the lowest effective dose for the shortest duration, and that the taper schedule is designed to reach that goal. The MSD Veterinary Manual offers balanced pharmacology summaries that can support your explanation.

Does Corticosteroid Therapy Differ for Canine Atopic Dermatitis Compared with Human Atopic Dermatitis?

The underlying inflammatory pathways overlap, but the practical approach differs in several ways. Human guidelines emphasize topical calcineurin inhibitors as steroid-sparing agents, and these drugs also have a role in veterinary dermatology, though cost and availability limit their use in dogs. Topical corticosteroids in humans are often used long term on sensitive areas such as the face and eyelids, where contact allergy to the steroid itself is a recognized concern, as documented in eyelid dermatitis case series. In dogs, systemic therapy is used more readily because oral dosing is simpler for owners and the adverse effect profile is better tolerated than in humans. Barrier dysfunction is central in both species, and lipid-containing emulsions support repair in dogs as they do in people.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Medicinal potential of <i>Panax ginseng</i> and its ginsenosides in atopic dermatitis treatment.. 2020.
• Pimecrolimus -- an anti-inflammatory drug targeting the skin.. 2004.
• Topical tacrolimus for atopic dermatitis.. 2015.
• Eyelid dermatitis: experience in 203 cases.. 2002.
• Role of the epidermal barrier in atopic dermatitis.. 2009.
• Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis.. 2001.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Corticosteroid Therapy in Feline Inflammatory Bowel Disease: Dosing and Monitoring
• Corticosteroid Therapy in Feline Diseases: Special Considerations
• Corticosteroid Use in Canine Dermatology: A Practical Approach
• Corticosteroid Therapy in Canine Inflammatory Diseases: Balancing Efficacy and Safety
• Therapeutic Decision Framework for Canine Osteoarthritis: NSAIDs, Adjuvants, and Monitoring

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.